Autoimmune Presentation Rhupus Like of lung cancer non-small cells

Authors

DOI:

https://doi.org/10.52076/eacad-v3i2.168

Keywords:

Rheumatoid Arthritis, Lupus, Autoimmunity.

Abstract

Introduction: Rhupus, or Rhupus Syndrome, is a rare rheumatologic disease characterized by the overlapping of Systemic Lupus Erythematosus and Rheumatoid Arthritis in patients meeting SLICC and ACR/EULAR criteria. Objective: To describe the clinical case of a patient with non-small cell lung cancer presenting with Rhupus Syndrome and to review the literature on Rhupus and its clinical features. Methodology: Case report type of study descriptive qualitative with information obtained directly from the medical records kept during hospitalization. Discussion: Rhupus Syndrome, characterized by the overlapping of SLE and RA, has two most common presentations, the first are patients who begin with RA, and then are diagnosed with SLE, comprising 2/3 of the cases of Rhupus. The second presentation consists of patients initially with SLE or with both diseases diagnosed at the beginning. As this is a rare syndrome, there are no validated diagnostic criteria for this disease. Conclusion: Although the interposition of rheumatologic diseases is not rare, Rhupus has an estimated prevalence of 0.09% of the population. Diagnosis may be difficult because there are no well-defined diagnostic criteria and because of its rarity; however, this diagnosis may be determinant for an adequate approach to the patient and a better prognosis, reducing complications related to SLE and/or RA.

References

ANTONIHGNI, Luca, et al. Rhupus: a systematic literature review. Autoimmunity Reviews, p. 102-612, 2020.

AZMECUA-GUERRA, LM. Overlap between systemic lupus erythematosus and rheumatoid arthritis: is it real or just an illusion?. J. Rheumatol; 36:4-6, 2009.

BRITO, Tayra H G; et al. Relato de Caso–Síndrome de RUPHUS: uma excepcionalidade diagnostica. Brazilian Journal of Health Review, v. 4, n. 2, p. 6714-6719, 2021.

DANION, François et al. Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients. Rheumatic and Musculoskeletal Diseases, v. 3, n. 2, p. e000555, 2017.

LI, Jing et al. Clinical analysis of 56 patients with rhupus syndrome: manifestations and comparisons with systemic lupus erythematosus: a retrospective case–control study. Medicine (Baltimore), v. 93, n. 10, 2014.

LIU, T et al. Clinical and laboratory profiles of rhupus syndrome in a Chinese population: a single-centre study of 51 patients. Lupus; 23:958-63, 2014.

SIMON, T.A, et al. Prevalence of co- existing autoimmune disease in rheumatoid arthritis: a cross-sectional study. Adv Ther; 34:2481–90, 2017.

SOLIS CARTAS, Urbano et al. Rhupus syndrome. A rare combination. Revista Colombiana de Reumatología, v. 24, n. 4, p. 237-241, 2017.

WALLACE, Daniel J. et al. Dubois’ lupus erythematosus and related syndromes. 8th edition. Pg 543-544, 2013.

ZIEGELASCH M, et al. Antibodies against carbamylated proteins and cyclic citrullinated pep- tides in systemic lupus erythematosus: results from two well-defined-European cohorts. Arthritis Res Ther; 18:289, 2016.

Published

2022-06-16

Issue

Section

Health and Biological Sciences

How to Cite

Barbosa Filho, R. ., Menezes, T. B. M. de ., Dias, P. R. de S. ., Silva, E. T. M. F. ., Lustosa, K. ., & Costa, F. A. M. da . (2022). Autoimmune Presentation Rhupus Like of lung cancer non-small cells. E-Acadêmica, 3(2), e4432168. https://doi.org/10.52076/eacad-v3i2.168